Cardiac Effects of Novel Histamine H2 Receptor Agonists
- 1 December 2021
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 379 (3) , 223-234
Abstract
In an integrative approach, we studied cardiac effects of recently published novel H2 receptor agonists in the heart of mice that overexpress the human H2 receptor (H2-TG), littermate wild type control mice (WT) and in isolated electrically driven muscle preparations from patients undergoing cardiac surgery. Under our experimental conditions, the H2 receptor agonists UR-Po563, UR-MB-158 and UR-MB-159 increased force of contraction in left atrium from H2-TG with pEC50 values of 8.27, 9.38, and 8.28, respectively, but not in WT. Likewise, UR-Po563, UR-MB-158 and UR-MB-159increased the beating rate in right atrium from H2-TG with pEC50 values of 9.01, 9.24, and 7.91, respectively, but not in WT. These effects could be antagonized by famotidine, a H2 receptor antagonist. UR-Po563 (1 µM) increased force of contraction in Langendorff perfused hearts from H2-TG but not WT. Similarly, UR-Po563, UR-MB-158 or UR-MB-159 increased the left ventricular ejection fraction in echocardiography of H2-TG. Finally, UR-Po563 increased force of contraction in isolated human right atrial muscle strips. The contractile effects of UR-Po563 in H2-TG were accompanied by an increase in the phosphorylation state of phospholamban. In summary, we report here three recently developed agonists functionally stimulating human cardiac H2 receptors in vitro and in vivo. We speculate that these compounds might be of some merit to treat neurological disorders if their cardiac effects are blocked by concomitantly applied receptor antagonists that cannot pass through the blood-brain barrier or might be useful to treat congestive heart failure in patients. Significance Statement Recently, a new generation of H2R agonists has been developed as possible treatment option for Alzheimer9s disease. Here, possible cardiac (side) effects of these novel H2R agonists have been evaluated.Keywords
This publication has 43 references indexed in Scilit:
- Cardiac overexpression of the human 5-HT4receptor in miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- A Novel Data Mining Approach to the Identification of Effective Drugs or Combinations for Targeted Endpoints?Application to Chronic Heart Failure as a New Form of Evidence-based MedicineCardiovascular Drugs and Therapy, 2004
- Overexpression of the Catalytic Subunit of Protein Phosphatase 2A Impairs Cardiac FunctionJournal of Biological Chemistry, 2004
- Histamine H1 and H2 Receptor Gene and Protein Levels Are Differentially Expressed in the Hearts of Rodents and HumansThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Rapid desensitization of the histamine H2 receptor on the human monocytic cell line U937European Journal of Pharmacology: Molecular Pharmacology, 1994
- Positive inotropic activity of the novel histamine H2-receptor agonist, amthamine, on the human heart in vitroGeneral Pharmacology: The Vascular System, 1994
- In vitro cardiac pharmacology of the new histamine H2-receptor agonist amthamine: Comparisons with histamine and dimapritInflammation Research, 1993
- Reduced positive inotropic effects in diseased human ventricular myocardiumCardiovascular Research, 1986
- Possible value of H2-receptor agonists for treatment of catecholamine-insensitive congestive heart failurePharmacology & Therapeutics, 1984
- Effective Stimulation of Cardiac Contractility and Myocardial Metabolism by Impromidine and Dimaprit—Two New H2-Agonistic Compounds—In the Surviving, Catecholamine-Insensitive Myocardium After Coronary OcclusionJournal of Cardiovascular Pharmacology, 1982